Unbiased avidity-based isolation of antigen-specific T cells
Open Access
- 8 July 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (7) , e014960
Abstract
Background: Cancer immunotherapies have significantly improved treatment efficacy and patient survival by exploiting antigen-specific T cells to eliminate cancer cells. However, current approaches for identifying and isolating antigen-specific T cells typically require prior knowledge of target antigens, limiting discovery, and reducing the ability to consistently detect rare tumor-reactive T cells. We therefore sought to develop an unbiased platform for the identification and enrichment of antigen-specific T cells using naturally processed and presented tumor antigens. Methods: We developed ATTACH (Assessment of T cells Tethered to Antigen Class I Histocompatibility), a microfluidic platform that applies controlled shear stress and leverages tumor cells as a natural source of endogenous major histocompatibility complex (MHC)-peptide complexes to isolate antigen-specific T cells based on MHC/peptide binding avidity. ATTACH was evaluated in both human and mouse systems for its ability to enrich rare tumor-reactive T-cell populations and deplete bystander virus-specific T cells. Results: ATTACH resulted in up to a 10-fold enrichment of antigen-specific T cells across both human and mouse systems, enabling the isolation of clonotypes present at frequencies as low as 0.1%. In addition to enriching rare tumor-reactive T cells, ATTACH efficiently depleted virus-specific bystander T cells. Conclusions: ATTACH provides a streamlined and unbiased approach for the rapid identification and isolation of antigen-specific T cells, and may facilitate the optimization of cellular therapies for the treatment of solid tumors.Keywords
Funding Information
- Exon 20 Group (N/A)
- Rexanna's Foundation (Bruce Campbell Research Grant)
- Rexanna's Foundation (The Lance Bertrand Research Grant)
- American Association for Cancer Research (AACR) Career Development Award in Lung Cancer Research (23-20-01-REUB)
- Troper Wojcicki Foundation (N/A)
- Happy Lungs Project (N/A)
- Department of Defense Lung Cancer Research Program (Idea Development Award / HT9425-23-1-1021)
- Waun Ki Hong Lung Cancer Research Fund (N/A)
- Petrin Fund (N/A)
- LUNGevity Foundation (EGFR Resisters/LUNGevity Foundation EGFR-positive)
- LUNGevity Foundation (RETpositive/LUNGevity Translational Research Award)
- Cancer Prevention and Research Institute of Texas (High Impact High Reward Award / RP210137)
- Cancer Prevention and Research Institute of Texas (Individual Investigator Research Award / RP230363)
- Cancer Prevention and Research Institute of Texas (Individual Investigator Research Award / RP260357)
- NCI (SBIR Innovative Concept Award / 75N91025C00012)
- MD Anderson’s Lung Cancer Moon Shot (N/A)
- Salgado Family Charitable Fund (N/A)
- University Cancer Foundation Institutional Research Grant program at the University of Texas MD Anderson Cancer Center (N/A)
- NIH/NCI (R21 / R21CA283852)
This publication has 57 references indexed in Scilit:
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJournal of Clinical Investigation, 2014
- The WT hemochromatosis protein HFE inhibits CD8+ T‐lymphocyte activationEuropean Journal of Immunology, 2014
- Mechanical regulation of cancer cell apoptosis and autophagy: Roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPKBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Low-Affinity T Cells Are Programmed to Maintain Normal Primary Responses but Are Impaired in Their Recall to Low-Affinity LigandsCell Reports, 2013
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsNature Medicine, 2013
- Analysis, Isolation, and Activation of Antigen-Specific CD4+ and CD8+ T Cells by Soluble MHC-Peptide ComplexesFrontiers in Immunology, 2013
- Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung CancerJournal of Surgical Research, 2011
- A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assaysJournal of Immunological Methods, 2002
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996